Part 3: Newer therapies for ANCA-associated vasculitis

Clinical and Experimental Rheumatology

Volumn 25, Issue 1 SUPPL. 44, 2007, Pages

  Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

B cell; Deoxyspergualin; Immunosuppression; Mycophenolate mofetil; Rituximab; Therapy; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISOLONE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; GIANT CELL ARTERITIS; HUMAN; INFECTION RISK; LEUKOPENIA; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; REPRODUCTIVE TOXICITY; RETREATMENT; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 34247504612     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (29)

1. KALSCH AI, SCHMITT WH, BREEDIJK A et al.: In vivo effects of cyclic administration of 15-deoxyspergualin on leucocyte function in patients with Wegener's granulomatosis. Clin Exp Immunol 2006; 146: 455.
2. SCHMITT WH, BIRCK R, HEINZEL PA et al.: Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005; 20: 1083.
3. BIRCK R, WARNATZ K, LORENZ HM et al.: 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003; 14: 440.
4. IMAI H, HOTTA O, YOSHIMURA M et al.: Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy. Clin Exp Nephrol 2006; 10: 40.
5. BIRCK R, NEWMAN M, BRAUN C et al.: 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant 2006; 21: 58.
6. FLOSSMANN O, COHEN TERVAERT JW, HELLMICH B et al.: Deoxyspergaulin for refrcatory wegener's granulomatosis. In: 13th International ANCA/ vasculitis workshop. L. F. Flores-Suarez, ed, Cancun 2007.
7. KOUKOULAKI M, JAYNE DR: Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 2006; 102: c100.
8. STASSEN PM, COHEN TERVAERT JW, STEGEMAN CA: Induction of remission in active ANCA-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2006; 19: 19.
9. JOY MS, HOGAN SL, JENNETTE JC, FALK RJ, NACHMAN PH: A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725.
10. METZLER C, FINK C, LAMPRECHT P, GROSS WL, REINHOLD-KELLER E: 2004. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004; 43: 315.
11. GROUP, E. V. S. 2007.
12. ITO-IHARA T, ONO T, NOGAKI F et al.: Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract 2006; 102: c35.
13. JAYNE DR, CHAPEL H, ADU D et al.: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Qjm 2000; 93: 433.
14. CHAN AT,FLOSSMANN O, MUKHTYAR C, JAYNE DR, LUQMANI RA: The role of biologic therapies in the management of systemic vasculitis. Autoimmun Rev 2006; 5: 273.
15. HUUGEN DH, XIAO A, van ESCH RJ et al.: Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005; 167: 47.
16. LITTLE MA, BHANGAL G, SMYTH CL et al.: Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of antineutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 2006; 17: 160.
17. BOOTH AD, JEFFERSON HJ, AYLIFFE W, ANDREWS PA, JAYNE DR: Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002; 61: 559.
18. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351.
19. STONE JH, HOLBROOK JT, MARRIOTT MA et al.: Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54: 1608.
20. BOOTH AL, HARPER T, HAMMAD P et al.: Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717.
21. FLENDRIE M. VISSERS WH, CREEMERS MC, de JONG EM, van de KERKHOF PC, van RIEL PL: Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: R666.
22. STOKES MB, FOSTER K, MARKOWITZ GS et al.: Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400.
23. SCHMITT WH, HAGEN EC, NEUMANN I, NOWACK R, FLORES-SUAREZ LF, van der WOUDE FJ: Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440.
24. HALE G: Recent developments in humanized MAbs for immunotherapy: a personal tribute to Dr. Martin Lockwood. Transfus Sci 1999; 21: 181.
25. WALSH M, CHAUDHRY A, JAYNE D: Long-term follow-up of patients with refrcatory ANCA-associated vasculitis treated with Alemtuzumab (CAMPATH 1-H). In 13th International ANCA/vasculitis workshop. L.F. Flores-Suarez, ed, Cancun 2007.
26. LOCKWOOD CM, HALE G, WALDMAN H, JAYNE DR: Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003; 42: 1539.
27. DAIKELER T, KOTTER I, BOCELLI TYNDALL C et al.: Haematopoietic stem cell transplantation for vasculitis including Behçet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Ann Rheum Dis 2007; 66: 202.
28. KUNITOMI A, ISHIKAWA T, TAJIMA K, KONAKA Y, YAGITA M: Bone marrow transplantation with a reduced-intensity conditioning regimen in a patient with Wegener granulomatosis and therapy-related leukemia. Int J Hematol 2006; 83:262.
29. TYNDALL A, SACCARDI R: Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol 2005; 141: 1.